[go: up one dir, main page]

PE20141472A1 - PHARMACEUTICAL COMPOSITION THAT INCLUDES ISOMETAMIDIUM CHLORIDE IN SOLUTION FOR THE TREATMENT OF TRYPANOSOMIASIS IN ANIMALS - Google Patents

PHARMACEUTICAL COMPOSITION THAT INCLUDES ISOMETAMIDIUM CHLORIDE IN SOLUTION FOR THE TREATMENT OF TRYPANOSOMIASIS IN ANIMALS

Info

Publication number
PE20141472A1
PE20141472A1 PE2014001030A PE2014001030A PE20141472A1 PE 20141472 A1 PE20141472 A1 PE 20141472A1 PE 2014001030 A PE2014001030 A PE 2014001030A PE 2014001030 A PE2014001030 A PE 2014001030A PE 20141472 A1 PE20141472 A1 PE 20141472A1
Authority
PE
Peru
Prior art keywords
trypanosomiasis
animals
treatment
solution
pharmaceutical composition
Prior art date
Application number
PE2014001030A
Other languages
Spanish (es)
Inventor
Cordero Auristela Gonzalez
Roviro Alberto Ochoa
Original Assignee
Invest Farmaceuticas Y Veterinarias S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963763&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141472(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Invest Farmaceuticas Y Veterinarias S L filed Critical Invest Farmaceuticas Y Veterinarias S L
Publication of PE20141472A1 publication Critical patent/PE20141472A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Communication Control (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) CLORURO DE ISOMETAMIDIUM MICRONIZADO A UNA CONCENTRACION DE 1 A 4% (P/V); B) ISOPROPILIDENOGLICEROL O GLICERINFORMAL A UNA CONCENTRACION DE 40 A 95% (P/V); C) UN POLIOL A UNA CONCENTRACION DE 0 A 50% (P/V); D) 15-HIDROXIESTEARATO DE POLIETILENGLICOL A UNA CONCENTRACION DE 1 A 5% (P/V); E) EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES EN SOLUCION TALES COMO i) PROPIL GALATO ENTRE 0,02 Y 0,05%, ii) POLIVINILPIRROLIDONA ENTRE 0,5 Y 5%, iii) N-METIL-2-PIRROLIDONA ENTRE 1 Y 20%, Y iv) 2-(2-ETOXIETOXI)ETANOL ENTRE 1 Y 10%. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE LA TRIPANOSOMIASIS Y ELIMINACION DE PARASITOS GASTROINTESTINALES Y PULMONARES EN ANIMALESIT REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES: A) MICRONIZED ISOMETAMIDIUM CHLORIDE AT A CONCENTRATION OF 1 TO 4% (W / V); B) ISOPROPYLIDENOGLYCEROL OR GLYCERINFORMAL AT A CONCENTRATION OF 40 TO 95% (W / V); C) A POLYOL AT A CONCENTRATION OF 0 TO 50% (P / V); D) POLYETHYLENE GLYCOL 15-HYDROXIESTEARATE AT A CONCENTRATION OF 1 TO 5% (W / V); E) PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS IN SOLUTION SUCH AS i) PROPYL GALATE BETWEEN 0.02 AND 0.05%, ii) POLYVINYLPYRROLIDONE BETWEEN 0.5 AND 5%, iii) N-METHYL-2-PYRROLIDONE BETWEEN 1 AND 20%, AND iv) 2- (2-ETHOXYETOXY) ETHANOL BETWEEN 1 AND 10%. SUCH COMPOSITION IS USEFUL FOR THE TREATMENT OF TRYPANOSOMIASIS AND ELIMINATION OF GASTROINTESTINAL AND PULMONARY PARASITES IN ANIMALS

PE2014001030A 2012-01-24 2012-07-19 PHARMACEUTICAL COMPOSITION THAT INCLUDES ISOMETAMIDIUM CHLORIDE IN SOLUTION FOR THE TREATMENT OF TRYPANOSOMIASIS IN ANIMALS PE20141472A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201230092A ES2416004B1 (en) 2012-01-24 2012-01-24 PHARMACEUTICAL COMPOSITION THAT INCLUDES ISOMETAMIDIUM CHLORIDE IN SOLUTION FOR THE TREATMENT OF TRIPANOSOMIASIS IN ANIMALS.

Publications (1)

Publication Number Publication Date
PE20141472A1 true PE20141472A1 (en) 2014-11-05

Family

ID=46963763

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001030A PE20141472A1 (en) 2012-01-24 2012-07-19 PHARMACEUTICAL COMPOSITION THAT INCLUDES ISOMETAMIDIUM CHLORIDE IN SOLUTION FOR THE TREATMENT OF TRYPANOSOMIASIS IN ANIMALS

Country Status (16)

Country Link
AP (1) AP2014007798A0 (en)
AR (1) AR089037A1 (en)
BR (1) BR112014016926A8 (en)
CL (1) CL2014001780A1 (en)
CO (1) CO6990714A2 (en)
CR (1) CR20140278A (en)
DO (1) DOP2014000161A (en)
EC (1) ECSP14010152A (en)
ES (1) ES2416004B1 (en)
GT (1) GT201400159A (en)
MA (1) MA35868B1 (en)
MX (1) MX2014008172A (en)
NI (1) NI201400075A (en)
PE (1) PE20141472A1 (en)
UY (1) UY34479A (en)
WO (1) WO2013110830A1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2024008B (en) * 1978-06-28 1983-02-16 Merck & Co Inc Compositions for treating trypanosomiasis infections
GB8805286D0 (en) * 1988-03-05 1988-04-07 Schering Agrochemicals Ltd Trypanocides
US5496830A (en) * 1994-09-14 1996-03-05 Johns Hopkins University Inhibition of hemoflagellates by camptothecin compounds
DE19854143A1 (en) * 1998-11-24 2000-05-25 Chambord Ltd Antiprotozoal composition useful for treating e.g. piroplasmosis, malaria and sleeping sickness comprises pentamidine and an additional biocide
FR2819188B1 (en) * 2001-01-08 2003-03-14 Virbac Sa WATER-SOLUBLE PULVERULENT OR GRANULATED COMPOSITIONS BASED ON PHENANTHRIDINES AND USES THEREOF
AR060926A1 (en) * 2007-05-14 2008-07-23 Ciriaco Quiroga PROPOFOL TRANSPARENT ANESTHETIC SOLUTION, WITH LOW VENOUS IRRITATION.
KR20080102010A (en) * 2007-05-17 2008-11-24 대원제약주식회사 Injectable compositions comprising propofol and methods for preparing the same
DE102008007381A1 (en) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidines and guanidines and their derivatives for the treatment of diseases
WO2011042565A2 (en) * 2009-10-09 2011-04-14 Instituut Voor Tropische Geneeskunde Antiprotozoal activity

Also Published As

Publication number Publication date
MX2014008172A (en) 2014-10-06
UY34479A (en) 2013-07-31
MA35868B1 (en) 2014-12-01
DOP2014000161A (en) 2014-08-15
GT201400159A (en) 2015-11-19
AR089037A1 (en) 2014-07-23
ES2416004B1 (en) 2014-01-28
CO6990714A2 (en) 2014-07-10
ES2416004A1 (en) 2013-07-29
BR112014016926A8 (en) 2017-07-04
BR112014016926A2 (en) 2017-06-13
CL2014001780A1 (en) 2014-10-24
ECSP14010152A (en) 2015-08-31
WO2013110830A1 (en) 2013-08-01
CR20140278A (en) 2014-12-02
NI201400075A (en) 2015-04-13
AP2014007798A0 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
CY1123476T1 (en) NUCLEAR TRANSPORT MODIFIERS AND THEIR USES
CY1122730T1 (en) 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND THEIR USES
EA201591363A1 (en) TIADIAZOLE ANALOGUES AND METHODS OF TREATMENT OF STATES ASSOCIATED WITH SMN DEFICIENCY
MA37400A1 (en) Cyclil compounds are not heterogeneous as mek inhibitors
EA201690287A1 (en) 1,4-DESIGNED ANALOGUES OF PYRIDAZIN QUINOLINE AND METHODS OF TREATING CONDITIONS ASSOCIATED WITH SMN-DEFICIENCY
CL2012001836A1 (en) Pyrazole compounds, crth2 antagonist; pharmaceutical composition; use in the treatment of inflammatory, infectious, immunoregulatory disorders, respiratory diseases, gastrointestinal or ailments, among others.
CO6491060A2 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
DOP2015000170A (en) CHEMICAL COMPOUNDS
EA201290116A1 (en) NEW COMPOSITIONS OF 1- [2- (2,4-DIMETHYLPHENYLSULPHANIL) PHENYL] PIPERASINE
EA201690679A1 (en) STABLE PHARMACEUTICAL COMPOSITION CONTAINING AMLODIPIPIN AND VALSARTAN
BR112015007592A2 (en) enalapril compositions
MX2015003732A (en) TREATMENT OF SLIGHT AND MODERATE ALZHEIMER DISEASE.
CL2012002358A1 (en) Use of an oral pharmaceutical composition comprising: i) n- [8- (2-hydroxybenzoyl) amino] caprilic acid or a salt thereof, ii) vitamin b12 and optionally iii) folic acid to prepare a medicament useful in the treatment of Vitamin B12 deficiency conditions.
CY1118645T1 (en) USE OF PIDOTIMOD IN HEALTH TREATMENT
PE20141472A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES ISOMETAMIDIUM CHLORIDE IN SOLUTION FOR THE TREATMENT OF TRYPANOSOMIASIS IN ANIMALS
MX2017007856A (en) Oral care composition.
EA201500128A1 (en) PEDIATRIC LIQUID COMPOSITIONS FOR ORAL ADMINISTRATION CONTAINING NEPATUTANEAN
EA201500368A1 (en) PHARMACEUTICAL COMPOSITION OF 1-ADAMANTYLETHYLOXY-3-MORFOLIN-2-PROPANOL OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR TREATING CARDIOVASCULAR PATHOLOGY
RU2012100120A (en) ACARICID PHARMACEUTICAL COMPOSITION BASED ON THE SALT OF QUATERNARY PHOSPHONY, SUBSTITUTED DINITROBENZOFURAXAN AND XYMEDON HYDROCHLORIDE
EA201500366A1 (en) APPLICATION OF 1-ADAMANTYLETYLOXY-3-MORFOLINO-2-PROPANOL OR ITS PHARMACEUTICALLY ADOPTABLE SALTS IN PHARMACEUTICAL COMPOSITIONS AS A NEURORTHINOPROTECTOR
CU20160048A7 (en) PHARMACEUTICAL DOSAGE FORMS INCLUDING 1- [6- (MORFOLIN-4-IL) PIRIMIDIN-4-IL] -4- (1H-1,2,3-TRIAZOL-1-IL) -1H-PIRAZOL-5-OLATO OF SODIUM
CU20130165A7 (en) MODIFIED RELEASE OF 4-METHYL-3 - [[- 4- (3- PIRIDINIL) -2-PYRIMIDINYL] AMINO] -N-5- (4- METHYL-1H-IMIDAZOL-1- IL) -3- (TRIFLUOROMETIL) FENIL] SOLUBILIZED BENZAMIDE USING ORGANIC ACIDS
IN2013MU02587A (en)
IN2013MU02585A (en)
PE20170069A1 (en) {ACID 4 - [(2 - {[3,5-BIS (TRIFLUORomethyl) BENZYL] - [(2R, 4S) -1- (ETOXICARBONYL) -2-ETHYL-6- (TRIFLUOROMETIL) -1,2,3, 4-TETRAHYDROQUINOLIN-4-IL] AMINO} PYRIMIDIN-5-IL) OXI] BUTANOIC} AS INHIBITOR OF CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) AND COMPOSITIONS THAT INCLUDE IT

Legal Events

Date Code Title Description
FD Application declared void or lapsed